Mifepristone (RU486), the first clinically available antiprogestin, has generated great interest since its discovery in the early 1980s. Today, it is recognized that mifepristone, along with other antiprogestins, has a potentially significant therapeutic role in human health and disease, with likely applicability to a variety of pregnancy-related conditions (e.g., management of labor) and to contraception, endometriosis, and cancer, among others. But because mifepristone has been studied and used most widely as a means of nonsurgical abortion, political issues have thus far limited research on the drug and prevented its introduction into the U.S. market.
This book provides an unbiased evaluation of current knowledge about both the fundamental nature of antiprogestins as well as their possible use in treating numerous diseases and conditions, and it contains recommendations for future research.
Institute of Medicine. 1993. Clinical Applications of Mifepristone (RU486) and Other Antiprogestins: Assessing the Science and Recommending a Research Agenda. Washington, DC: The National Academies Press. https://doi.org/10.17226/2203.
|Uses of Antiprogestins: The Reproductive Cycle (Part I)||19-25|
|Uses of Antiprogestins: The Reproductive Cycle (Part II)||26-35|
|Other Therapeutic Uses of Antiprogestins||36-51|
|Antiglucocorticoid Effects of Antiprogestins||52-56|
|Animals as Models for Studying Antiprogestins||57-62|
|Appendix A: Agenda fr the IOM Workshop 'Antiprogestins: Assessing the Science'||63-68|
|Appendix B: Background Papers and Presentations (In Order of Presentation at IOM Workshop)||69-70|
|B1. 1993: RU 486--A Decade on Today and Tomorrow||71-119|
|B2. Overview and Background: Mechanism of Action of Antiprogestins||120-138|
|B3. The Use of Antiprogestins in the Reproductive Cycle||139-147|
|B4. Potential Contraceptive Effects of Antigestogens||148-163|
|B5. Use of Antiprogestins Before 63 Days of Amenorrhea||164-173|
|B6. Uses of Antiprogestins After 63 Days of Amenorrhea||174-182|
|B7. Comments on Session II||183-188|
|B8. Use of Antiprogestins in the Management of Endometriosis and Leiomyoma||189-209|
|B9. Antiprogestins and the Treatment of Breast Cancer||210-228|
|B10. Uses of RU 486 as an Antiglucocoticoid||229-242|
|B11. Primate Models for the Study of Antiprogestins in Reproductive Medicine||243-252|
|B12. ANtiprogestogens: Perspectives from a Global Research Program||253-277|
|Appendix C: Observers at the Workshop on Antiprogestins||278-280|
The Chapter Skim search tool presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter. You may select key terms to highlight them within pages of each chapter.
The National Academies Press (NAP) has partnered with Copyright Clearance Center's Rightslink service to offer you a variety of options for reusing NAP content. Through Rightslink, you may request permission to reprint NAP content in another publication, course pack, secure website, or other media. Rightslink allows you to instantly obtain permission, pay related fees, and print a license directly from the NAP website. The complete terms and conditions of your reuse license can be found in the license agreement that will be made available to you during the online order process. To request permission through Rightslink you are required to create an account by filling out a simple online form. The following list describes license reuses offered by the National Academies Press (NAP) through Rightslink:
Click here to obtain permission for the above reuses.If you have questions or comments concerning the Rightslink service, please contact:
Rightslink Customer Care
Tel (toll free): 877/622-5543
To request permission to distribute a PDF, please contact our Customer Service Department at 800-624-6242 for pricing.
To request permission to translate a book published by the National Academies Press or its imprint, the Joseph Henry Press, pleaseclick here to view more information.